Court Denies FLORASIS Trademark Due to Likeness with Existing FLORA Brand
A significant trademark judgment has been passed by the High Court, which has far-reaching implications for businesses and trademark owners. The court has rejected the trademark application for “FLORASIS” due to its similarity with an existing trademark “FLORA”. This ruling is being hailed as a win for trademark owners who have worked hard to establish their brand identity.
The case involved a company that had applied to register the trademark “FLORASIS” for their products. However, the owner of the existing trademark “FLORA” objected to the application, citing similarity between the two marks. The objection was initially rejected by the trademark registry, but the owner of “FLORA” appealed to the High Court.
The High Court heard the appeal and considered the similarities and differences between the two trademarks. The court applied the test of “likelihood of confusion” to determine whether the average consumer would be confused between the two marks. After careful consideration, the court ruled in favor of the owner of “FLORA”, holding that the trademark “FLORASIS” was indeed similar and could cause confusion among consumers.
The court’s decision was based on the principle that a trademark should be unique and distinctive, and that similarity with an existing mark can dilute the brand identity and cause harm to the owner of the existing mark. The court also considered the fact that the products for which the “FLORASIS” trademark was applied were similar to those for which the “FLORA” trademark was registered.
This judgment is significant because it highlights the importance of conducting thorough trademark searches before applying for a new trademark. It also emphasizes the need for businesses to be mindful of existing trademarks and to ensure that their brand identity is unique and distinctive. The ruling will have implications for businesses and trademark owners, who will need to be more vigilant in protecting their brand identity and avoiding conflicts with existing trademarks.
In conclusion, the High Court’s rejection of the “FLORASIS” trademark application is a win for trademark owners who have worked hard to establish their brand identity. The ruling emphasizes the importance of uniqueness and distinctiveness in trademarks and highlights the need for businesses to be mindful of existing trademarks. The judgment will have far-reaching implications for businesses and trademark owners, and will likely lead to more careful consideration of trademark applications in the future.
Sun Pharmaceutical Industries receives US FDA approval for cutting-edge skin treatment device.
Sun Pharmaceutical Industries has received approval from the US Food and Drug Administration (FDA) for a new medical device designed to treat actinic keratoses (AK), a skin condition caused by prolonged sun exposure. AK is characterized by the appearance of red, rough patches on sun-exposed areas, and if left untreated, can develop into skin cancer. The condition often affects areas such as the face, scalp, and arms, and is a common concern for individuals who spend a significant amount of time outdoors.
The newly approved device is an upgraded version of the BLU-U Blue Light Photodynamic Therapy system, which has been enhanced with advanced LED technology. This new technology makes the device more compact and easier to operate compared to its predecessor, which used fluorescent tubes. The LED BLU-U device is used in conjunction with LEVULAN KERASTICK, a topical solution containing aminolevulinic acid, to treat mild to moderate AK. The combination of the device and topical solution provides a effective treatment option for individuals affected by this condition.
The FDA approval was granted through the Real-Time Review Program, which underscores the strength of Sun Pharma’s submission. The company believes that the new LED BLU-U device will enhance both user experience and treatment outcomes. The compact and easy-to-use design of the device is expected to improve patient comfort and compliance, while the advanced technology is likely to provide more effective treatment results. With the approval of this new device, Sun Pharma is well-positioned to provide a valuable treatment option for individuals affected by AK, and to help prevent the development of skin cancer.
The approval of the new LED BLU-U device is a significant milestone for Sun Pharma, and demonstrates the company’s commitment to developing innovative treatments for skin conditions. The device is expected to be a valuable addition to the company’s portfolio of dermatology products, and will provide healthcare professionals with a new option for treating AK. Overall, the approval of the new LED BLU-U device is a positive development for individuals affected by AK, and highlights the ongoing efforts to develop effective treatments for skin conditions.
As India crosses the ‘Tropic of Cancer’ in terms of rising caseload, Pfizer announces plans to introduce novel oncology treatments.
India is facing a significant rise in cancer cases, with estimates suggesting that 1 in 9 Indians is at risk of developing cancer in their lifetime. To address this growing issue, American pharmaceutical company Pfizer is planning to launch several new oncology drugs in the country. These drugs will target various types of cancer, including multiple myeloma, breast cancer, and bladder cancer. Pfizer’s senior medical director, Dr. Pankaj Gupta, stated that the company’s pipeline includes several molecules at different stages of development, which are being developed to address unmet medical needs in areas such as breast cancer, lung cancer, and colorectal cancer.
Pfizer is focusing on precision medicine, immunotherapy, and CAR-T cell therapy to transform cancer care. The company plans to launch three new therapies in India: elranatamab for multiple myeloma, sasanlimab for bladder cancer, and vepdegestrant for breast cancer. These drugs have shown promising results in clinical trials and are expected to provide new treatment options for patients.
Dr. Gupta emphasized that Pfizer aims to introduce these drugs in a way that complements national health priorities and expands access to cancer treatment. The company is working closely with state health systems and has multiple affordability solutions for patients, including patient assistance programs. Pfizer is also engaging with healthcare policy partners to shape cancer-related policies and improve awareness, diagnosis, and timely treatment.
One of the key areas of focus for Pfizer is antibody-drug conjugates (ADCs), which combine monoclonal antibodies with cytotoxic agents for targeted cancer cell destruction. The company has already developed molecules in the ADC space and plans to launch new ones in the coming years. Dr. Gupta highlighted the potential of ADCs to provide more precise and effective treatment options, reducing damage to healthy cells and improving patient outcomes.
Pfizer’s plans to launch new oncology drugs in India are significant, given the country’s growing cancer burden. With an estimated 1.57 million new cancer cases expected in 2023, India is set to become the cancer capital of the world. The company’s focus on precision medicine, immunotherapy, and CAR-T cell therapy, as well as its commitment to making its innovations accessible and affordable, is expected to have a positive impact on cancer care in India. Overall, Pfizer’s plans to launch new oncology drugs in India are a step in the right direction, and the company’s efforts to make these medicines accessible and affordable will be critical in addressing the country’s growing cancer burden.
PGIMER’s Transfusion Medicine Department Collects 117 Units of Blood, Sets Up Next Donation Camp at Glenmark Pharmaceuticals, Nalagarh on May 15
The Department of Transfusion Medicine at PGIMER, Chandigarh, recently conducted two blood donation camps in the city, with the goal of ensuring an adequate blood supply for patients in need. The first camp was held on May 14, 2025, at the Community Center in Manimajra, in association with the Chandigarh Municipal Corporation. Under the leadership of Dr. Suchet Sachdev, a total of 42 blood units were collected from volunteer donors.
A second camp was also held on the same day at the Community Centre in Sector 28, Chandigarh, in association with the Chandigarh Municipal Corporation. This camp, led by Dr. Ekta Paramjit, collected 75 blood units. The Department of Transfusion Medicine expressed its gratitude to all the donors who participated, noting that their contributions will help cater to the needs of critically ill patients in the institute.
The blood donation camps are part of the department’s ongoing efforts to ensure a steady supply of blood and blood components for patients. The donated blood will be used to support the treatment of patients at PGIMER, Chandigarh. The department is committed to continuing its life-saving mission and has scheduled another blood donation camp for May 15, 2025, in association with Glenmark Pharmaceuticals Ltd. The camp will be held at the company’s premises in Nalagarh, starting at 10:00 a.m.
Individuals interested in participating in the upcoming camp can contact the Senior Resident from PGIMER or Mr. Yash Pal for more information. The department encourages all eligible individuals to come forward and donate blood, as their contributions can help save lives. By supporting blood donation camps like these, individuals can make a significant difference in the lives of patients in need of blood transfusions. The Department of Transfusion Medicine is dedicated to continuing its efforts to ensure a safe and adequate blood supply, and the support of volunteer donors is crucial to achieving this goal.
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.